ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study
|First Received Date ICMJE||December 9, 2006|
|Last Updated Date||September 12, 2017|
|Start Date ICMJE||December 7, 2006|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE||Not Provided|
|Original Primary Outcome Measures ICMJE||Not Provided|
|Change History||Complete list of historical versions of study NCT00410241 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study|
|Official Title ICMJE||ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study|
This study will examine genome sequencing in clinical research. Genome sequencing is a process in which researchers analyze (or sequence) part or all of the genome from a single person. The human genome is the material in cells that includes thousands of genes. Gene changes that cause or contribute to disease can be passed on from one generation to the next. This study first focuses on heart disease. Later, researchers hope to study other conditions and genes, with the eventual goal of sequencing most or all of participants genes.
Participants ages 45 to 65 years of age and who do not smoke, may be eligible for this study. Patients will come to the NIH Clinical Research Center for an initial study to last about half a day. They will donate a blood sample and complete a short survey. Then they will meet the genetic counselor to learn more about genome sequencing. Those who join the study will undergo the following procedures and evaluations:
Each patient will receive a letter with results of the clinical laboratory values and evaluations. There will be recommendations for follow-up with the patient s doctors. Risks in this study include exposure to radiation from the CT test. The radiation amount used is about the same that a person normally receives from natural sources, such as from the sun, outer space, and radioactive materials found naturally in the earth s air and soil. Another slight risk involves reactions to a contrast agent that may be used in the echocardiogram. Side effects can be headache, nausea or vomiting, a warm sensation, and dizziness.
With the samples that patients provide, researchers will start by sequencing about 400 genes related to heart disease. Analysis will take months to complete. Genome sequencing is difficult to do, and researchers have much to learn about the genes they sequence and the gene changes they find. If the researchers find gene changes that are important to the health of a participant, they will contact that participant and give him/her the choice of learning such results.
This study may or may not have a direct benefit for participants. Patients would get free clinical testing for cholesterol, diabetes, and other conditions, as well as information about gene changes. Knowledge gained will benefit people in the future as researchers learn about the relationship between gene changes and health.
The purpose of ClinSeq is to pilot large-scale medical sequencing (LSMS) in a clinical
research setting. By sequencing a person s exome or genome and returning relevant and
individual results to that person, we will begin investigating some of the technical, medical,
and genetic counseling issues that accompany the implementation of LSMS in the clinical
setting. Specifically, we seek to develop technologic and procedural infrastructures to
facilitate this type of research and demonstrate that it is feasible to sequence and interpret
large amounts of genomic sequence data and return individual results to subjects.
A cohort of ~1,500 individuals selected from the surrounding general population will be
evaluated at the NIH Clinical Center for a common set of cardiovascular phenotypic
features, including, but not limited to, coronary artery calcification, lipid profiles, and blood
pressure. Participants will be selected to fall within a spectrum of coronary artery
calcification from normal to disease phenotype based on Framingham scores. During their
initial visit, participants will undergo a clinical evaluation, targeted clinical tests, and blood
sample collection for genomic analysis. Additionally, they will be asked to provide baseline
information about pertinent health behavior and a family history. During their initial visit
and as the study progresses, participants may be asked to complete surveys related to
various socio-behavioral aspects of their participation, such as their attitudes toward
learning individual results or health behaviors related to receipt of results.
Most participants will have exome sequencing (ES), and selected participants will have
genome sequencing (GS). ClinSeq will further our understanding of the relative
contributions of rare versus common variants to the architecture of common disease.
Currently, only direct sequencing can address the question of the frequency of rare variants,
which is of particular interest to us. We will test for associations of genomic variants, some
of which will be rare, with the cardiovascular phenotype in question, as well as other
phenotypes. We have developed analytic algorithms to distinguish potentially pathogenic
genetic alterations from normal variation (Johnston et al., 2012; Ng et al., 2013; Gonsalves
et al., 2013). Sequence variants deemed clinically relevant will be validated in a CLIAcertified
laboratory and the results offered to that subject. ClinSeq is designed to provide
the long-term potential for pursuing many different clinical projects.
Relatives of ClinSeq participants may be invited to enroll in the project for more limited
studies if their participation aids our understanding of the gene variants detected in the
probands. For example, these relatives may undergo genetic testing for co-segregation of
known or suspected disease-causing variants, and/or phenotyping relevant to the disease in
We aim to pilot procedures for generating data, address some of the analytical hurdles of
interpreting these data, and develop approaches for the medical and counseling challenges
of utilizing the relevant data for clinical research.
|Study Type ICMJE||Observational|
|Study Design ICMJE||Not Provided|
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Not Provided|
|Study Population||Not Provided|
|Intervention ICMJE||Not Provided|
|Study Groups/Cohorts||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Recruiting|
|Estimated Enrollment ICMJE||2000|
|Completion Date||Not Provided|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||
We plan to recruit a cohort whose risk to develop coronary artery disease will range from less than 5 percent, based on the 10-year-risk provided by the Framingham risk score, to greater than 10 percent, and including those with known coronary artery disease. The 10-year-risk will be measured by the Framingham risk score based on LDL cholesterol levels.
Individuals eligible for Bins 1-3 of this study will be 45 to 65 years of age, and individuals eligible for Bin 4 must be 35-65 years of age. We selected this cutoff as we are interested in recruiting a cohort whose coronary artery calcification (CAC) measurements range from normal to diseased, and it has been shown that abnormal CAC is infrequent below this age. Also, individuals eligible for this study will be required to have a primary care physician or equivalent with whom we can communicate in the event we uncover a condition that merits follow-up. The exception to this includes individuals in Group A2 who are recruited through the community outreach being done by Ms. Sandra Epps. These individuals will not be required to have a primary care physician, although we will strongly recommend that they attend a community health clinic for follow-up on clinical recommendations from the study. Additionally, individuals eligible for this study will be required to be non-smokers at the time of enrollment, for our purposes defined as someone who has not smoked regularly during the previous 12 months.
Due to the large number of individuals to be recruited and the intention to follow this cohort longitudinally, we will focus our efforts on the metropolitan DC and Baltimore areas (in order to minimize reluctance to participate because of travel limitations). If recruitment is below anticipated levels, we may seek additional subjects from the Richmond, VA metropolitan area. Individuals who are not local to these areas may be considered for participation if they are part of other protocols within NHLBI, and travel to the NIH Clinical Research Center on a regular basis for follow-up, or if they are willing to travel to the NIH as needed for protocol participation (at their own expense). Bin 4 participants will be eligible to have the cost of their transportation, meals and lodging covered if they must travel >500 miles for their clinical visits.
An eligibility screen will be performed by telephone to ascertain age, basic demographics, smoking history, and presence or absence of known cardiovascular disease. We intend to recruit persons of both sexes, of diverse ethnic and racial categories, and from various socio-economic backgrounds.
The eligibility for Group B is distinct from Group A. Group B eligibility requires:
Individual excluded from participating in the study include: (1) first-degree relatives of enrolled ClinSeq participants (unless they fall into Group B); and (2) individuals who are directly involved with gathering data and analyzing the clinical and genotyping data, including the Principal Investigator, the Associate Investigators, the ClinSeq staff involved with the subjects at the clinical level (such as the Nurse Practitioner, Genetic counselor, etc.), and the staff at NISC involved with generating and analyzing the sequence data ; and (3) individuals who request access to their raw sequence data for analysis outside of ClinSeq ; and (4) individuals who are already enrolled in another study that provides genome or exome sequencing, such as the GENE-FORECAST Study (14-HG-0048).
|Ages||45 Years to 65 Years (Adult)|
|Accepts Healthy Volunteers||Yes|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT00410241|
|Other Study ID Numbers ICMJE||070002
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )|
|Study Sponsor ICMJE||National Human Genome Research Institute (NHGRI)|
|Collaborators ICMJE||Not Provided|
|PRS Account||National Institutes of Health Clinical Center (CC)|
|Verification Date||August 22, 2017|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP